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Innate and chronic immunodeficiencies represent a group of heterogeneous 
dysfunctions of the immune system resulting in impaired defense on infections and 
tumors. Genetically determined disorders of the protective immune function, commonly 
referred as Primary Immuno Deficiency diseases (PID), and it have been recognised 
clinically already 60 years ago with the identification of X-linked agammaglobulinemia. 
Today, the group of PID involves over 280 distinct entities which are scattered to present 
as phagocytic disorders, complement deficiencies, T-cell deficiencies and – 
predominantly - antibody disorders. PID are not rare diseases; with a summarised 
prevalence ranging from 1 in 250 to 1 in 500. However, they are misdiagnosed in many 
cases because of their subtle clinical image and their prolonged course of disease, 
which often worsens the outcome. Although increasingly becoming appreciated as a 
major health problem, there is a lack of diagnostic procedures and sophisticated 
therapeutic perspectives that would allows upon earliest possible diagnosis and a 
satisfactory treatment of patients with primary immunodeficiency diseases. 
Primary and acquired immunodeficiencies strongly influence prognosis and outcome of 
patients. The targeted identification of such patients represents a diagnostic challenge. 
Diagnostic strategies depend on the clinical presentation, patients’ history, and age. 
Clinical manifestation of primary immunodeficiencies can start in early childhood but also 
in adults, based on severity and modifying conditions. Frequently, PID are characterised 
by hypogammaglobulinemia of the IgG, IgM, and/or IgA isotype, respectively, and a 
resulting clinical presentation consisting of recurrent and chronic infections, particularly 
of the respiratory, intestinal and genitourinary systems. Awareness of possibly 
underlying immunodeficiencies and targeted diagnostics is crucial for early diagnosis 
and therapy. 
In children, majority of most severe immunodeficiencies can be detected by new born 
screening tests carry out with dried blood spot samples (DBSS). Serious impairment of 
the immune response due to inborn errors of T- or B-lymphocyte differentiation results in 
immunodeficiency syndromes such as Severe Combined Immunodeficiency (SCID) or 
Agammaglobulinemia (XLA, ARA). The fatal outcome of these syndromes – if 
undiscovered and untreated within the first year of life - and the availability of well-
established treatment options justify a general newborn screening program for those 
severe immunodeficiency diseases.  
Lymphocytes can be diagnosed efficiently by flow cytometry in adults and in children 
suspicious on immunodeficiencies. Immunophenoptyping allows differentiation and 
functional description of immune cells, including lymphocytes, dendritic cells, monocytes, 
and polymorphnuclear cells. This is of particular relevance in diagnosis of 
immunodeficiencies, but also in autoinflammatory, autoimmune, and allergic diseases. 
For differential diagnosis, functional assays with lymphocytes and phagocytes are 
essential and can be done in a simple and reproducible way.  
Currently, the rationale behind the treatment of antibody deficiency diseases is to restore 
physiological levels of serum immunoglobulins by intravenous or subcutaneous 
substitution, which has been shown to prevent or alleviate infectious episodes. Cellular 
and combined immunodeficiencies are eligible to stem cell transplantation. 
